

ToxTracker Discussion: A Potential New Approach Method for Carcinogenicity Testing

ICCVAM MDF PROPOSAL



Toxys Inc. New York, NY










- Born from transcriptomic assessment of genotoxic and non-genotoxic carcinogens.
- Established for identifying direct and indirect genotoxic agents.
- Constructed mouse ES cells with stable BAC GFP-reporters to detect:
 - **Bulky Adducts**
 - DNA breaks
 - **Oxidative stress**
 - **UPR** activation •





- p53 tumor suppressor activation
- DNA damage, oxidative stress, osmotic shock, ribonucleotide depletion, apoptosis

Section 1: ToxTracker Assay









Ames pos. MN pos.

Conc. (uM)

Ames neg. MN pos.


* 2-fold GFP reporter induction is limit for positive ToxTracker result.

Section 1: Enhanced Understanding

Ames neg. MN pos.

Ames neg. MN pos.











Section 1: ToxTracker Dose Range Finding Assay






Wild type mouse stem cells




Seed cells in 96-wells plate




Expose cells to the compounds (24 h.)

Day 2



Dissolve compound in DMSO or H₂O






Day 3



Cell count by flow cytometry



Min 0.1 Conc. (µM) Max 10

Dose range finding

Cytotoxicity

0.01

Rel


- Compound solubility
- Autofluorescence
- Metabolic activation (+S9)






Section 1: ToxTracker Definitive Assays

| Da | y 1 |
|--------------------|-----------------------|
| DNA DAMAGE | OXIDATIVE STRESS |
| | |
| | |
| Bscl2-GFP | Srxn1-GFP |
| | |
| Rtkn-GFP | Blvrb-GFP |
| P53 ACTIVATION | PROTEIN DAMAGE |
| Btg2-GFP | Ddit3-GFP |
| Six independent GF | P reporter cell lines |
| | |




Seed cells in 96-wells plate





Expose cells to the compounds (24 h.)

Data analysis using Toxplot software

















Compound requirement

- Pharmaceuticals (top concentration 1 mM): 5-10 mg
- Chemicals (top concentration 10 mM): 50-100 mg

Turn around time


- Standard service: 2-3 weeks
- Express service: 3 days

Throughput

• Standard full test (dose finding, three repeats -/+ S9): 1-25 compounds/week



Section 1: Practical Facts



Intermediates (occupational toxicology)








- ToxTracker is currently used to identify genotoxic hazards and determine mode-ofaction (MOA).
- Used to discriminate direct genotoxicants from those with an indirect mechanism of action (e.g., oxidative stress inducers).
- Since direct (DNA-reactive) and indirect genotoxic effects may initiate the carcinogenic process, quantitative methods have been used to assess potential safety margins

Section 2: Context of use








Section 2: MOA with ToxTracker ACE

- Multiplexed DNA staining after 4h and 24h exposure
- Determine cell cycle distribution and polyploid induction
- Aneugens have a 4 Hr G2/M block and 24 Hr >5% polyploidy




Aneugens – Tubulin poisons

Cell cycle


Threshold



- Analysis using PROAST to calculate BMDs (BMR100)
- Potency ranking for prioritizing further in vivo testing, especially for datapoor compounds
- Has been included post hoc to assess the reference chemicals used during Genetox21 (EPA).



Section 2: Quantitative analysis of ToxTracker data





Section 2: Context of Use Summary

Hazard ID

- 384-well, Rtkn and Bscl2 cell lines quick genotoxic predictions
- Full panel of cell lines to classify MOA

Risk Assessment

- Amenable to BMD analysis, and deriving AEDs
- Quantitative PODs overlap with those derived from in vivo studies

3R's Aligned

for moving away from animal testing

Modalities/Products Tested

Gaps for Detecting Carcinogens

- Presently qualified to detect genotoxicants covers genotoxic carcinogens
- Requires further investigation for carcinogens acting by other MIEs

• As a stand-alone assay, better predicts genotoxic carcinogens than other in vitro tools, providing trust

Pharmaceuticals, agrochemicals, industrial chemicals, UVCBs, nanomaterials, polymers, LNPs, oligos





Section 3: Important Key Events (KEs) in Carcinogenesis

Over 13,000 chemicals used to draft an AOP based on rodent carcinogens (Cayley et al, 2023)








Section 3: Important Key Events (KEs) in Carcinogenesis

- Over 13,000 chemicals used to draft an AOP based on rodent carcinogens (Cayley et al, 2023)
- DNA alkylation, oxidative stress and protein reactivity were top 3 KEs linked to a positive cancer bioassay










Section 3: Important Key Events (KEs) in Carcinogenesis

- Over 13,000 chemicals used to draft an AOP based on rodent carcinogens (Cayley et al, 2023)
- DNA alkylation, oxidative stress and protein reactivity were top 3 KEs linked to a positive cancer bioassay




These pathways are the focus of ToxTracker








Section 3: Example Oxidant KBrO₃







Chromosomal aberrations" (KE 1636), and that different repair pathways are involved in repairing different types of DNA damage.

Mechanistic information to support AOPs




- Thousands of compounds tested so far
- Initially validated with Toxcast DB* and ECVAM-suggested** libraries
- Interlaboratory OECD ring trial confirmed superior single assay sensitivity and specificity

| Test name | Sens |
|----------------------------|------|
| Regulatory | |
| Bacterial reversion (Ames) | I |
| Chromosome aberrations | |
| Mammalian mutation | |
| Screening | |
| ToxTracker | |
| Ames MPF | |
| GreenScreen HC | |
| | |

* https://www.epa.gov/chemical-research/toxcast-chemicals ** Kirkland et al., 2016

| Specificity (%) | MOA |
|-----------------|----------------------------|
| | |
| 77 | - |
| 55 | - |
| 48 | - |
| | |
| 95 | yes |
| 63 | - |
| 95 | - |
| | 77 55 48 95 63 |








International OECD inter-laboratory validation

- Extended 7 lab validation study w/ 64 compounds (2017-2022)
- Chemical selection was sector agnostic, ~half genotoxicants
- Conducted in accordance with OECD guidance document 34
- Expert Validation Management Team (VMT)
- Currently drafting a test guideline for WNT review

| VMT Members | Industry | Locatio |
|-------------------|---------------------|---------|
| David Kirkland | Kirkland consulting | UK |
| Philippe Vanparys | Gentoxicon | BE |
| Jan van Benthem | RIVM | NL |
| Els Adriaens | Adriaens consulting | BE |
| Giel Hendriks | Toxys | NL |

* Sensitivity indicates the number of carcinogens that are positive in a genotoxicity test, the specificity indicated the percentage of non-carcinogens that give a negative results in a genotoxicity test. Sensitivity refers to the number of false-negative tests. Specificity indicates the fraction of false-positive test results.


Section 3: External Validation





Participating Laboratories


Pfizer (US) Genentech (US) Roche (EU) Procter & Gamble (US) Corteva agriscience (US) Charles River (CA) Covance (EU)







- Thousands of compounds tested so far
- Initially validated with Toxcast DB* and ECVAM-suggested** libraries
- Interlaboratory OECD ring trial confirmed superior single assay sensitivity and specificity



* https://www.epa.gov/chemical-research/toxcast-chemicals ** Kirkland et al., 2016

Non-Carcinogens (n=32)

10 of 10 Positive


84.4% Sensitivity and 91.2% specificity for detecting in vivo genotoxicants with 83% between lab reproducibility (Only Rtkn/Bscl2 Evaluated)





Section 3: BMD-based correlation between ToxTracker and in vivo MN

- Bscl2-GFP and Rtkn-GFP BMDs overlap with those obtained from in vivo MN studies
- This has potential to replace the in vivo POD metrics, supporting the 3Rs









FIGURE 1 Illustration of a SAS bootstrap output for a single study. Control ratios were calculated 5000 times; the distribution of Log10 bootstrapped ratios was examined and compared to expectations for a normal distribution (e.g., histogram and box plot). The geometric 95th and 99th percentiles were used to determine the cut-off values for determination of a positive response (Table 1). LogGFPRatio = Log10 GFP Ratio.




Section 4: Assay Variability

Assessed variability in vehicle controls from >100 studies using bootstrapping techniques (5000 iterations, log-transformed data)





Section 4: Robust Response Criteria



Summary of bootstrap analysis to determine fold-TABLE 1 change cut-off values for delineation of significant positive responses. Values shown are geometric 95th (GM95th) and 99th percentiles (GM99th) of ratio distributions.

| Reporter | GM 95th |
|----------|---------|
| Bscl2 | 1.46 |
| Rtkn | 1.55 |
| Btg2 | 1.46 |
| Srxn1 | 1.58 |
| Blvrb | 1.62 |
| Ddit3 | 1.52 |
| Average | 1.51 |

- Negative (< 1.5-fold induction)
- Equivocal (1.5 to < 2.0-fold induction)

| GM 99th |
|---------|
| 1.66 |
| 1.76 |
| 1.64 |
| 1.85 |
| 1.88 |
| 1.69 |
| 1.74 |

Positive (\geq 2.0-fold induction) •








Section 4: Consistent culturing practices

- Metabolic activation of compounds by PB/Nf induced rat liver S9
- Same exposure paradigm used absence or presence of 0.4% S9, for 24 hours.
- Facilitates direct comparison of treatment conditions within the assay



ced rat liver S9 sence of 0.4% S9, for 24 hours. ons within the assay



Section 4: Intra-laboratory reproducibility

- The within-laboratory reproducibility (WLR) was up to 98% (73%-98% across participants) and the overall between-laboratory reproducibility (BLR) was 83%.
- Evaluating just Rtkn and Bscl2, using consensus calling and the standard ± S9 protocol
- So far transferability is high, as the assay is conducted in multiple other labs worldwide

| Lab | Tested compounds | Reproducible | Non-reproducible | WLR |
|-----|------------------|--------------|------------------|-------|
| 1 | 30 | 29 | 1 | 96,7% |
| 2 | 24 | 22 | 2 | 91,7% |
| 3 | 25 | 23 | 2 | 92,0% |
| 4 | 26 | 19 | 7 | 73,1% |
| 5 | 24 | 20 | 4 | 83,3% |
| 6 | 30 / / | 24 | 6 | 80,0% |
| 7 | 27 | 22 | 5 | 81,5% |
| | | | | |





Concluding SWOT for detecting carcinogens

Strengths

- Qualified/validated for detecting direct and indirect genotoxicants
- High throughput, simple gating logic, and easily transferred to other laboratories.
- Used for hazard ID with data supporting quantitative risk assessment processes

Weaknesses

their uniqueness in discerning carcinogens from non-carcinogens.

Opportunity

other cell lines for use in carcinogenicity testing.

Threats

- Genomics technologies for identifying direct genotoxicants (i.e., ecNGS)
- Other genetox NAMs

• Other cell lines (Srxn1, Blvrb and Ddit3) have not been extensively evaluated despite being selected for

• To create and test a library focused on the 3 major KEs in Cayley et al (2023) and adequately assess the





Directly connect with us:

Dan Roberts MS Director, Sales & BD d.roberts@toxys.com

The value of understanding



Visit www.toxys.com or contact us at info@toxys.com








Back up slides





• ToxTrackerACE integrates cell cycle analysis into the ToxTracker assay to discern aneugens



Refresher: Biological Coverage








ToxTracker correlates with regulatory genetox assays

Rtkn-GFP reporter for DNA strand breaks is predictive for micronucleus (MN) and chromosome aberration (CA) assays



*Comparison with ECVAM library of reference compounds, Kirkland et al 2016





Genotoxic MoA investigation in ToxTracker

| | | | In vitro | | vitro | | In vivo | | | ToxTracker | | |
|-------------|-------------------------------|------------|----------|-----|-------|----|---------|----|-----|------------|---|--|
| | Compound | CAS number | Ames | MLA | MN | СА | MN | CA | TgR | Genotoxic | МоА | |
| Group I: G | enotoxic carcinogens | | | | | | | | | | | |
| 18 | Cadmium Chloride | 10108-64-2 | E | | Р | Р | Р | Р | | N | Oxidative stress | |
| 22 | 4-nitroquinoline-1-oxide | 56-57-5 | Р | Р | Р | Р | Р | Р | Р | Р | DNA reactive, oxidative stress | |
| Group II: (| Genotoxic non-carcinogens | | | | | | | | | | | |
| 25 | p-Phenylenediamine 2HCl | 624-18-0 | Р | Р | Р | Р | N | | | Р | DNA reactive, oxidative stress | |
| 26 | 8-Hydroxyquinoline | 148-24-3 | Р | | | Р | N | | | Р | Indirect genotoxin, oxidative stress, protein | |
| 32 | Phenol | 108-95-2 | Ν | | Р | Р | Р | N | | Р | Indirect genotoxin, oxidative stress | |
| Group III: | Non-genotoxic carcinogens | | | | | | | | | | | |
| 34 | Lead (ii) acetate trihydrage | 6080-56-4 | Ν | | Р | E | E | Р | | E | Oxidative stress | |
| 35 | 2-Phenylphenol sodium salt | 6152-33-6 | Р | | | E | Ν | N | | N | Oxidative stress, protein reactive | |
| 38 | Cyclosporin A (CsA) | 59865-13-3 | N | | | | N | | | N | Protein reactive | |
| Group IV: | Non-genotoxic non-carcinogens | | | | | | | | | | | |
| 43 | Tunicamycin | 11089-65-9 | Ν | | Р | | N | | | N | Protein reactive | |
| 44 | p-Nitrophenol (4-nitrophenol) | 100-02-7 | N | | Е | Р | N | | | N | Protein reactive | |
| 45 | Phenanthrene | 85-01-8 | Р | | Е | E | | | | N | Oxidative stress, protein reactive | |
| 46 | Tertiarybutylhydroquinone | 1948-33-0 | N | | Р | Р | N | N | | N | Oxidative stress, protein reactive | |
| 54 | Chlorpheniramine maleate | 113-92-8 | N | P | | Р | N | | | N | Oxidative stress | |
| 58 | Allyl alcohol | 107-18-6 | P | P | | Р | N | | | N | Oxidative stress | |

Blue: expected MoA oxidative stress

Green: expected MoA protein unfolding

